INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Key Highlights
- ➤VOCERYQ received FDA accelerated approval to reduce surgery frequency in adults with RRP
- ➤VOCERYQ is the first FDA-approved DNA medicine, validating INOVIO’s platform technology
- ➤Full VOCERYQ commercial launch is expected in first quarter 2027
- ➤November public offering generated $80.5 million in net proceeds for launch
- ➤Cash runway extends into late fourth quarter 2027, excluding VOCERYQ revenue
Expert Statements
Dr. Jacqueline Shea, President and Chief Executive Officer of INOVIO
“We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients. Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline.”
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights PR Newswire
* VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent Respiratory Papillomatosis (RRP) * VOCERYQ expected to be available to order and ship in approximately 60 days from the approval date with full commercial launch in first quarter 2027 * VOCERYQ represents the first FDA approved DNA medicine, validating INOVIO's novel platform technology * Net proceeds of $80.5 million from recently completed public offering supports the commercial launch of VOCERYQ * INOVIO to host a conference call on November 10, 2026 at 4:30 PM ET PLYMOUTH MEETING, Pa., Nov. 10, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter ended September 30, 2026 and provided an update on recent company developments. INOVIO's management will host a live conference call and webcast at 4:30 p.m. ET today to discuss third quarter 2026 results.
Get started
Create a free account to read the full story.